DOCSLIB.ORG

LIAISON® Mycoplasma Pneumoniae Igg

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LIAISON® Mycoplasma Pneumoniae Igg Infectious Disease Mycoplasma pneumoniae IgG, IgM The first fully automated solution for Mycoplasma pneumoniae antibody detection FOR OUTSIDE THE US AND CANADA ONLY Mycoplasma pneumoniae: an elusive pathogen • Mycoplasmas are the smallest self-replicating organisms that are capable of cell-free existence • Due to the lack of a cell wall, mycoplasmas do not respond to penicillins and other beta-lactams used for the treatment of bacterial pneumonia • Differential diagnosis of M. pneumoniae is crucial for effective patient management Infection and pathogenesis • Transmission of M. pneumoniae is primarily through aerosols from person to person, and cyclic epidemics of the bacterium are observed every 3-7 years, usually in the early autumn • The infection is most common in children aged 2-12, with 80% of adults being seropositive for IgG • M. pneumoniae is responsible for 10-30% of cases of Community Acquired Pneumonia (CAP) • CAP however only represents 10% of M. pneumoniae infections - other complications have been reported such as tracheobronchitis, upper respiratory tract disease, asthma and a significant rate of hospitalisation, especially in the elderly Clinical diagnostics - serology • IgM is a reliable marker of acute infection in children, but can present several limitations in adults: - IgM can persist for up to a year, therefore is not always indicative of acute infection - Approximately 20% of adults, especially the elderly, do not mount an IgM response, particularly in the case of re-infection • Due to the late elevation of IgG and the high seroprevalence in adults due to past infection, it is advisable, where possible, to test simultaneously for both IgG and IgM • A significant increase in IgG titre from paired specimens collected 2-3 weeks apart indicates current or recent infection PRIMARY INFECTION REINFECTION INTERPRETATION OF SEROLOGY RESULTS Result Indication IgG IgM IgG IgG No indication of Negative Negative M. pneumoniae infection Positive IgM or Positive Indication of current Negative infection AB concentration Indication of past Negative 1 week 3 weeks Time Positive infection LIAISON® Mycoplasma pneumoniae IgG and IgM assays The fully automated approach to M. pneumoniae antibody detection The unique practical and technological advantages of the LIAISON® systems, the quality of the reagents and antigen selection have been combined to create a new approach to Mycoplasma pneumoniae diagnosis. LIAISON® Mycoplasma pneumoniae IgG ABEI Diagnostic Sensitivity 94.2%* Magnetic Recombinant Anti- Anti-human Emitted light Particle P1 antigen M. pneumoniae IgG linked Diagnostic Specificity 98.8%* specific IgG to ABEI tracer LIAISON® Mycoplasma pneumoniae IgM ABEI Diagnostic Sensitivity 99.1%* Magnetic Recombinant Anti - Anti-human Emitted light Particle P1 antigen M. pneumoniae IgM linked Diagnostic Specificity 97.8%* + whole-cell lysate specific IgM to ABEI tracer As clinical findings are often insufficient to distinguish between Mycoplasma pneumoniae, and pneumonia caused by other pathogens, correct etiologic determination depends on differential laboratory diagnosis. Serology – the standard in laboratory diagnostics • Culture is 100% specific but is time-consuming and relatively insensitive • PCR is very sensitive but a positive result is not always indicative of infection • Complement fixation does not enable differentiation between antibody classes • Serology is the method of choice - presence of IgM and/or a significant rise in IgG antibodies always provides evidence of current/recent M. pneumoniae infection Optimal antigen selection • LIAISON® Mycoplasma pneumoniae IgG uses recombinant antigens against the 170-kDa P1 adhesion protein of M. pneumoniae • LIAISON® Mycoplasma pneumoniae IgM, in addition to the P1 antigen, incorporates whole-cell lysate Versatile testing possibilities • A three-fold, or greater, increase of IgG concentration in paired samples allows the diagnosis of current or recent infection • Careful calibration of the IgM cut-off allows for high assay sensitivity without compromise on specificity * Diagnostic specificity and sensitivity were assessed against EIA by testing 465 specimens (IgG) and 445 specimens (IgM) from a population with signs and symptoms of atypical pneumonia, collected in different laboratories and consensus with additional serological data was applied to define the expected results. Infectious Disease Mycoplasma pneumoniae Assays LIAISON® Mycoplasma pneumoniae IgG Number of tests 50 Assay format Indirect-semi-quantitative Method CLIA Antigen type Recombinant peptide P1 Conjugate MoAb to human IgG conjugated to isoluminol derivative Sample type 20 μl Serum / Plasma Integral on board stability 6 weeks Calibrators availability on board-positive and negative Calibration stability 4 weeks Controls availability Positive and Negative (40 test per control kit-code 317021) Controls stability once opened 6 weeks LIAISON® Mycoplasma pneumoniae IgM Number of tests 50 Assay format Indirect-qualitative Method CLIA Antigen type Recombinant peptide P1+Whole cell lysate Conjugate MoAb to human IgM conjugated to isoluminol derivative Sample type 20 μl Serum / Plasma Integral on board stability 8 weeks Calibrators availability on board-positive and negative Calibration stability 8 weeks Controls availability Positive and Negative (40 test per control kit-code 317031) Controls stability once opened 6 weeks Ordering Information Code LIAISON® Mycoplasma pneumoniae IgG 317020 LIAISON® Control Mycoplasma pneumoniae IgG 317021 LIAISON® Mycoplasma pneumoniae IgM 317030 LIAISON® Control Mycoplasma pneumoniae IgM 317031 AVAILABLE ON SYSTEMS Product availability subject to required regulatory approval M0870004252/D 02/19 DiaSorin S.p.A. Via Crescentino 13040 Saluggia (VC) - Italy Tel. +39.0161.487526 Fax: +39.0161.487670 www.diasorin.com E-mail: [email protected].
Load more

Recommended publications
  • Bacterial Communities of the Upper Respiratory Tract of Turkeys
    www.nature.com/scientificreports OPEN Bacterial communities of the upper respiratory tract of turkeys Olimpia Kursa1*, Grzegorz Tomczyk1, Anna Sawicka‑Durkalec1, Aleksandra Giza2 & Magdalena Słomiany‑Szwarc2 The respiratory tracts of turkeys play important roles in the overall health and performance of the birds. Understanding the bacterial communities present in the respiratory tracts of turkeys can be helpful to better understand the interactions between commensal or symbiotic microorganisms and other pathogenic bacteria or viral infections. The aim of this study was the characterization of the bacterial communities of upper respiratory tracks in commercial turkeys using NGS sequencing by the amplifcation of 16S rRNA gene with primers designed for hypervariable regions V3 and V4 (MiSeq, Illumina). From 10 phyla identifed in upper respiratory tract in turkeys, the most dominated phyla were Firmicutes and Proteobacteria. Diferences in composition of bacterial diversity were found at the family and genus level. At the genus level, the turkey sequences present in respiratory tract represent 144 established bacteria. Several respiratory pathogens that contribute to the development of infections in the respiratory system of birds were identifed, including the presence of Ornithobacterium and Mycoplasma OTUs. These results obtained in this study supply information about bacterial composition and diversity of the turkey upper respiratory tract. Knowledge about bacteria present in the respiratory tract and the roles they can play in infections can be useful in controlling, diagnosing and treating commercial turkey focks. Next-generation sequencing has resulted in a marked increase in culture-independent studies characterizing the microbiome of humans and animals1–6. Much of these works have been focused on the gut microbiome of humans and other production animals 7–11.
    [Show full text]
  • Calves Infected with Virulent and Attenuated Mycoplasma Bovis Strains Have Upregulated Th17 Inflammatory and Th1 Protective Responses, Respectively
    G C A T T A C G G C A T genes Article Calves Infected with Virulent and Attenuated Mycoplasma bovis Strains Have Upregulated Th17 Inflammatory and Th1 Protective Responses, Respectively Jin Chao 1,2,3,4, Xiaoxiao Han 1,2, Kai Liu 1,2, Qingni Li 1,2, Qingjie Peng 5, Siyi Lu 1,2, Gang Zhao 1,2, Xifang Zhu 1,2, Guyue Hu 1,2, Yaqi Dong 1,2, Changmin Hu 2, Yingyu Chen 1,2, Jianguo Chen 2, Farhan Anwar Khan 1, Huanchun Chen 1,2,3,4 and Aizhen Guo 1,2,3,4,* 1 The State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China 2 College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China 3 Hubei International Scientific and Technological Cooperation Base of Veterinary Epidemiology, Huazhong Agricultural University, Wuhan 430070, China 4 Key Laboratory of Development of Veterinary Diagnostic Products, Ministry of Agriculture, Huazhong Agricultural University, Wuhan 430070, China 5 Wuhan Keqian Biology Ltd., Wuhan 430223, China * Correspondence: [email protected]; Tel.: +86-27-8728-6861 Received: 15 June 2019; Accepted: 27 August 2019; Published: 28 August 2019 Abstract: Mycoplasma bovis is a critical bovine pathogen, but its pathogenesis remains poorly understood. Here, the virulent HB0801 (P1) and attenuated HB0801-P150 (P150) strains of M. bovis were used to explore the potential pathogenesis and effect of induced immunity from calves’ differential transcriptomes post infection. Nine one-month-old male calves were infected with P1, P150, or mock-infected with medium and euthanized at 60 days post-infection.
    [Show full text]
  • Role of Protein Phosphorylation in Mycoplasma Pneumoniae
    Pathogenicity of a minimal organism: Role of protein phosphorylation in Mycoplasma pneumoniae Dissertation zur Erlangung des mathematisch-naturwissenschaftlichen Doktorgrades „Doctor rerum naturalium“ der Georg-August-Universität Göttingen vorgelegt von Sebastian Schmidl aus Bad Hersfeld Göttingen 2010 Mitglieder des Betreuungsausschusses: Referent: Prof. Dr. Jörg Stülke Koreferent: PD Dr. Michael Hoppert Tag der mündlichen Prüfung: 02.11.2010 “Everything should be made as simple as possible, but not simpler.” (Albert Einstein) Danksagung Zunächst möchte ich mich bei Prof. Dr. Jörg Stülke für die Ermöglichung dieser Doktorarbeit bedanken. Nicht zuletzt durch seine freundliche und engagierte Betreuung hat mir die Zeit viel Freude bereitet. Des Weiteren hat er mir alle Freiheiten zur Verwirklichung meiner eigenen Ideen gelassen, was ich sehr zu schätzen weiß. Für die Übernahme des Korreferates danke ich PD Dr. Michael Hoppert sowie Prof. Dr. Heinz Neumann, PD Dr. Boris Görke, PD Dr. Rolf Daniel und Prof. Dr. Botho Bowien für das Mitwirken im Thesis-Komitee. Der Studienstiftung des deutschen Volkes gilt ein besonderer Dank für die finanzielle Unterstützung dieser Arbeit, durch die es mir unter anderem auch möglich war, an Tagungen in fernen Ländern teilzunehmen. Prof. Dr. Michael Hecker und der Gruppe von Dr. Dörte Becher (Universität Greifswald) danke ich für die freundliche Zusammenarbeit bei der Durchführung von zahlreichen Proteomics-Experimenten. Ein ganz besonderer Dank geht dabei an Katrin Gronau, die mich in die Feinheiten der 2D-Gelelektrophorese eingeführt hat. Außerdem möchte ich mich bei Andreas Otto für die zahlreichen Proteinidentifikationen in den letzten Monaten bedanken. Nicht zu vergessen ist auch meine zweite Außenstelle an der Universität in Barcelona. Dr. Maria Lluch-Senar und Dr.
    [Show full text]
  • Dynamic Dashboard - List of Bacteria with a Relevant AMR Issue
    14 May 2020 Dynamic Dashboard - List of bacteria with a relevant AMR issue Categorization and inclusion methodology for human bacterial pathogens The World Health Organization’s (WHO) Global Priority List of Antibiotic-Resistant Bacteria [1], the United States of America’s Centers for Disease Control and Prevention (CDC) Antibiotic Resistant Threats in the United States 2019 [2] and the bacteria included in the European Centre for Disease Prevention and Control’s (ECDC) European Antimicrobial Resistance Surveillance Network (EARS-Net) [3] were used to develop a combined list of priority bacteria with a drug-resistance issue. It was considered that all research into these bacteria, irrespective of the drug-resistance profile, would be relevant to advance efforts to address antimicrobial resistance. For the categorization process, only the bacterial genus level (noting the family Enterobacteriaceae was also included) was used and will be displayed. Table 1 list the genus included in categorization and the rules applied for inclusion based on the aforementioned priority lists. When projects included bacteria other than those listed in Table 1 an individual assessment was performed by the Secretariat to determine if there is a known drug-resistance issue. This assessment included searching the literature and reaching a consensus within the Secretariat if the bacteria has a known drug- resistance issue or not. Where consensus was not reached or there was ambiguity in the literature bacteria were parked and further investigation was conducted. The list of additional bacteria and the outcomes from the assessment are provided in Table 2 and 3. Please note that these lists will be continually updated.
    [Show full text]
  • DCMC Community Acquired Pneumonia Discussion and Review
    DELL CHILDREN’S MEDICAL CENTER EVIDENCE-BASED OUTCOMES CENTER ADDENDUM 3 Discussion and Review of the Evidence Contents 1 Etiology ........................................................................................................................................................... 2 1.1 Streptococcus pneumoniae ....................................................................................................................... 2 1.2 Mycoplasma pneumoniae ......................................................................................................................... 2 1.3 Haemophilus influenzae ........................................................................................................................... 2 1.4 Streptococcus pyogenes ........................................................................................................................... 2 1.5 Staphylococcus aureus ............................................................................................................................. 3 1.6 Viruses ...................................................................................................................................................... 3 1.7 Underimmunized patients ........................................................................................................................ 3 2 Diagnostic Evaluation ..................................................................................................................................... 4 2.1 History .....................................................................................................................................................
    [Show full text]
  • Ehrlichiosis in Brazil
    Review Article Rev. Bras. Parasitol. Vet., Jaboticabal, v. 20, n. 1, p. 1-12, jan.-mar. 2011 ISSN 0103-846X (impresso) / ISSN 1984-2961 (eletrônico) Ehrlichiosis in Brazil Erliquiose no Brasil Rafael Felipe da Costa Vieira1; Alexander Welker Biondo2,3; Ana Marcia Sá Guimarães4; Andrea Pires dos Santos4; Rodrigo Pires dos Santos5; Leonardo Hermes Dutra1; Pedro Paulo Vissotto de Paiva Diniz6; Helio Autran de Morais7; Joanne Belle Messick4; Marcelo Bahia Labruna8; Odilon Vidotto1* 1Departamento de Medicina Veterinária Preventiva, Universidade Estadual de Londrina – UEL 2Departamento de Medicina Veterinária, Universidade Federal do Paraná – UFPR 3Department of Veterinary Pathobiology, University of Illinois 4Department of Veterinary Comparative Pathobiology, Purdue University, Lafayette 5Seção de Doenças Infecciosas, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul – UFRGS 6College of Veterinary Medicine, Western University of Health Sciences 7Department of Clinical Sciences, Oregon State University 8Departamento de Medicina Veterinária Preventiva e Saúde Animal, Universidade de São Paulo – USP Received June 21, 2010 Accepted November 3, 2010 Abstract Ehrlichiosis is a disease caused by rickettsial organisms belonging to the genus Ehrlichia. In Brazil, molecular and serological studies have evaluated the occurrence of Ehrlichia species in dogs, cats, wild animals and humans. Ehrlichia canis is the main species found in dogs in Brazil, although E. ewingii infection has been recently suspected in five dogs. Ehrlichia chaffeensis DNA has been detected and characterized in mash deer, whereas E. muris and E. ruminantium have not yet been identified in Brazil. Canine monocytic ehrlichiosis caused by E. canis appears to be highly endemic in several regions of Brazil, however prevalence data are not available for several regions.
    [Show full text]
  • Sexually Transmitted Infections: Diagnosis and Management
    SEXUALLY TRANSMITTED INFECTIONS: DIAGNOSIS AND MANAGEMENT STEPHANIE N. TAYLOR, MD LSUHSC SECTION OF INFECTIOUS DISEASES MEDICAL DIRECTOR, DELGADO CENTER PERSONAL HEALTH CENTER NEW ORLEANS, LA INTRODUCTION Ê Tremendous Public Health Problem Ê AtitdAn estimated 15 m illion AiAmericans acqu ire an STD each year Ê $10 billion dollars in healthcare costs per year Ê Substantial morbidity/mortality Ê Ulcerative and non-ulcerative STDs associated with increased HIV transmission STI PRINCIPLES Ê Counseling – HIV infection, abstinence, and “safer sex” practices Ê STD Screening of asymptomatic individuals and those with symptoms Ê Patients with one STD often have another Ê Partners should be evaluated and treated empirically at the time of presentation STI PRINCIPLES Ê Serologic testing for syphilis should be done in all patients Ê HIV t esti ng sh ould be s trong ly encouraged in all patients (New CDC Recommendation for “Opt-Out” testing) Ê STDs are associated with HIV transmission Major STI Pathogens Ê Bacteria Ê Viruses Ê HSV I & II, HPV, Ê Neisseria HBV, HIV , gonorrhoeae, molluscum Haemophilus ducreyi, Ê Protozoa GdGardnere lla vag inali s Ê Trichomonas Ê Spirochetes vaginalis Ê Fungi Ê Treponema pa llidum Ê Candida albicans Ê Chlamydia Ê Ectoparasites Ê Chlamy dia Ê Phthiris pubis, trachomatis Sarcoptes scabei MAJOR STI SYNDROMES Ê GENITAL ULCER DISEASE Ê URETHRITIS/CERVICITIS Ê PELVIC INFLAMMATORY DISEASE Ê VAGINITIS Ê OTHER VIRAL STDs Ê ECTOPARASITES GENITAL ULCER DISEASE Differential Diagnosis: Ê STIs Ê Syphilis, Herpes, Chancroid Ê LGV,
    [Show full text]
  • Tick-Borne Disease Working Group 2020 Report to Congress
    2nd Report Supported by the U.S. Department of Health and Human Services • Office of the Assistant Secretary for Health Tick-Borne Disease Working Group 2020 Report to Congress Information and opinions in this report do not necessarily reflect the opinions of each member of the Working Group, the U.S. Department of Health and Human Services, or any other component of the Federal government. Table of Contents Executive Summary . .1 Chapter 4: Clinical Manifestations, Appendices . 114 Diagnosis, and Diagnostics . 28 Chapter 1: Background . 4 Appendix A. Tick-Borne Disease Congressional Action ................. 8 Chapter 5: Causes, Pathogenesis, Working Group .....................114 and Pathophysiology . 44 The Tick-Borne Disease Working Group . 8 Appendix B. Tick-Borne Disease Working Chapter 6: Treatment . 51 Group Subcommittees ...............117 Second Report: Focus and Structure . 8 Chapter 7: Clinician and Public Appendix C. Acronyms and Abbreviations 126 Chapter 2: Methods of the Education, Patient Access Working Group . .10 to Care . 59 Appendix D. 21st Century Cures Act ...128 Topic Development Briefs ............ 10 Chapter 8: Epidemiology and Appendix E. Working Group Charter. .131 Surveillance . 84 Subcommittees ..................... 10 Chapter 9: Federal Inventory . 93 Appendix F. Federal Inventory Survey . 136 Federal Inventory ....................11 Chapter 10: Public Input . 98 Appendix G. References .............149 Minority Responses ................. 13 Chapter 11: Looking Forward . .103 Chapter 3: Tick Biology, Conclusion . 112 Ecology, and Control . .14 Contributions U.S. Department of Health and Human Services James J. Berger, MS, MT(ASCP), SBB B. Kaye Hayes, MPA Working Group Members David Hughes Walker, MD (Co-Chair) Adalbeto Pérez de León, DVM, MS, PhD Leigh Ann Soltysiak, MS (Co-Chair) Kevin R.
    [Show full text]
  • Safety and Efficacy of Ceftaroline Fosamil in the Management of Community-Acquired Bacterial Pneumonia Heather F
    Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Scholarly Papers 2014 Safety and Efficacy of Ceftaroline Fosamil in the Management of Community-Acquired Bacterial Pneumonia Heather F. DeBellis Kimberly L. Barefield Philadelphia College of Osteopathic Medicine, [email protected] Follow this and additional works at: https://digitalcommons.pcom.edu/scholarly_papers Part of the Medicine and Health Sciences Commons Recommended Citation DeBellis, Heather F. and Barefield, Kimberly L., "Safety and Efficacy of Ceftaroline Fosamil in the Management of Community- Acquired Bacterial Pneumonia" (2014). PCOM Scholarly Papers. 1913. https://digitalcommons.pcom.edu/scholarly_papers/1913 This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by an authorized administrator of DigitalCommons@PCOM. For more information, please contact [email protected]. Open Access: Full open access to Clinical Medicine Reviews this and thousands of other papers at http://www.la-press.com. in Therapeutics Safety and Efficacy of Ceftaroline Fosamil in the Management of Community- Acquired Bacterial Pneumonia Heather F. DeBellis and Kimberly L. Tackett South University School of Pharmacy, Savannah, GA, USA. ABSTR ACT: Ceftaroline fosamil is a new fifth-generation cephalosporin indicated for the treatment of community-acquired bacterial pneumonia (CABP). It possesses antimicrobial effects against both Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), but not against anaerobes. Organisms covered by this novel agent that are commonly associated with CABP are Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Klebsiella pneumoniae; however, ceftaroline fosamil lacks antimicrobial activity against Pseudomonas and Acinetobacter species.
    [Show full text]
  • Sexually Transmitted Infections Treatment Guidelines, 2021
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized
    [Show full text]
  • Human Anaplasmosis and Anaplasma Ovis Variant
    LETTERS Human teria. A chest radiograph, computed ware (www.ebi.ac.uk/Tools/clustalw2/ tomography of the abdomen, and an index.html) and the GenBank/Europe- Anaplasmosis and echocardiograph of the heart showed an Molecular Biology database library Anaplasma ovis unremarkable results. Blood samples (http://blast.ncbi.nlm.nih.gov/Blast. Variant were negative for antibodies against cgi). Phylogenetic trees were con- cytomegalovirus, Epstein-Barr virus, structed by using MEGA 4 software To the Editor: Anaplasmosis is a hepatitis, HIV, mycoplasma, coxackie (www.megasoftware.net). disease caused by bacteria of the genus virus, adenovirus, parvovirus, Cox- The fi rst blood sample was posi- Anaplasma. A. marginale, A. centrale, iella burnetii, R. conorii, and R. typhi, tive for A. ovis by PCR; the other 2 A. phagocytophilum, A. ovis, A. bovis, and for rheumatoid factors. A lymph were negative. A 16S rRNA gene se- and A. platys are obligate intracellular node biopsy specimen was negative quence (EU448141) from the posi- bacteria that infect vertebrate and in- for infi ltration and malignancy. After tive sample showed 100% similarity vertebrate host cells. A. ovis, which is treatment with doxycycline (200 mg/ with other Anaplasma spp. sequences transmitted primarily by Rhipicepha- day for 11 days), ceftriaxone (2 g/day (A. marginale, A. centrale, A. ovis) lus bursa ticks, is an intraerythrocytic for 5 days), and imipenem/cilastatin in GenBank. Anaplasma sp. groEL rickettsial pathogen of sheep, goats, (1,500 mg/day for 1 day), the patient and msp4 genes showed a 1,650-bp and wild ruminants (1). recovered and was discharged 17 days sequence (FJ477840, corresponding Anaplasma spp.
    [Show full text]
  • Sexually Transmitted Diseases Treatment Guidelines, 2015
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Gonococcal Infections ...................................................................................... 60 Methods ....................................................................................................................1 Diseases Characterized by Vaginal Discharge .......................................... 69 Clinical Prevention Guidance ............................................................................2 Bacterial Vaginosis .......................................................................................... 69 Special Populations ..............................................................................................9 Trichomoniasis ................................................................................................. 72 Emerging Issues .................................................................................................. 17 Vulvovaginal Candidiasis ............................................................................. 75 Hepatitis C ......................................................................................................... 17 Pelvic Inflammatory
    [Show full text]